We came across a bullish thesis on Biogen Inc. on Investing With Purpose’s Substack. In this article, we will summarize the bulls’ thesis on BIIB. Biogen Inc.'s share was trading at $143.81 as of September 18th. BIIB’s trailing and forward P/E were 13.86 and 9.04 respectively according to Yahoo Finance. create jobs 51/Shutterstock.com Biogen (BIIB) enters its July 31 Q2 earnings with investor focus on the rollout of its Alzheimer’s drug lecanemab and the durability of its multiple sclerosis franchise. T ...